29 results found.

Chemotherapy-induced Nausea and Vomiting Clinical Trial using Fosaprepitant 150 mg; Fosaprepitant 60 mg; Fosaprepitant 20 mg; Placebo Fosaprepitant; Ondansetron

Merck Sharp & Dohme Corp. - Recruiting N/A to 17 years.
- A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy.
Fosaprepitant 150 mg; Fosaprepitant 60 mg; Fosaprepitant 20 mg; Placebo Fosaprepitant; Ondansetron

Post-Operative Nausea, or Post-Operative Vomiting Clinical Trial using Aprepitant; Placebo to match aprepitant; Ondansetron; Placebo to match ondansetron

Merck Sharp & Dohme Corp. - Recruiting N/A to 17 years.
- A Phase IIb, Partially-Blinded, Randomized, Active Comparator- Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting.
Aprepitant; Placebo to match aprepitant; Ondansetron; Placebo to match ondansetron

Chemotherapy-Induced Nausea and Vomiting Clinical Trial using Fosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron; Dexamethasone Placebo; Ondansetron Placebo; Rescue Therapy

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy.
Fosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron; Dexamethasone Placebo; Ondansetron Placebo; Rescue Therapy

Morning Sickness Clinical Trial using Diclegis; Placebo (Sugar Pill)

Duchesnay Inc. - Recruiting 12 years to 17 years.
- A Multicenter Trial of the Efficacy and Safety of Diclegisr for Nausea and Vomiting of Pregnancy in Pregnant Adolescents.
Diclegis; Placebo (Sugar Pill)

Nausea, Vomiting, or Glioma Clinical Trial using Aprepitant; Ondansetron

Duke University - Recruiting 18 years or older.
- A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen.
Aprepitant; Ondansetron

Emesis Clinical Trial using Dexamethasone, Ondansetron, Aprepitant; Arm A: Standard Anti-emetic regimen

Ottawa Hospital Research Institute - Recruiting 19 years or older.
- A Randomized, Phase IV Trial of Individualized Care Versus Standard Care, in the Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. The EPIC Study.
Dexamethasone, Ondansetron, Aprepitant; Arm A: Standard Anti-emetic regimen

Cancer, Nausea, or Vomiting Clinical Trial using Standardized Ginger extract

Helsinn Healthcare SA - Recruiting 18 years or older.
- Multicenter, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Activity of a Ginger (Zingiber Officinale) Food Supplement in the Management of Nausea in Patients Receiving Highly Emetogenic Treatments and Standard Anti-emetogenic Therapy..
Standardized Ginger extract

Chemotherapy-Induced Nausea and Vomiting Clinical Trial using Fosaprepitant; Dexamethasone; 5HT3

Hoosier Oncology Group - Recruiting 15 years or older.
- Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153.
Fosaprepitant; Dexamethasone; 5HT3

Chemotherapy Induced Nausea and Vomiting Clinical Trial using granisetron transdermal system; Granisetron IV

Prostrakan Pharmaceuticals - Recruiting 13 years to 17 years.
- An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancusor Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years).
granisetron transdermal system; Granisetron IV

Nausea, or Vomiting Clinical Trial using Aprepitant; Aprepitant Placebo; Ondansetron; Dexamethasone; Ondansetron Placebo; Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).

Merck Sharp & Dohme Corp. - Recruiting 21 years or older.
- A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC Regimes) With Broad Range of Tumor Types (KMEC Study).
Aprepitant; Aprepitant Placebo; Ondansetron; Dexamethasone; Ondansetron Placebo; Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).

Nausea and Vomiting Clinical Trial using ondansetron; ondansetron-betahistine

Yonsei University - Recruiting 20 years to 70 years.
- .
ondansetron; ondansetron-betahistine

Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nau Clinical Trial using Real Acupressure Band; Placebo Acupressure Band

University of South Florida - Recruiting 4 years to 18 years.
- Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy.
Real Acupressure Band; Placebo Acupressure Band

Patients With Gastroparesis Who Have Failed Standard Therapy Clinical Trial using Domperidone

University of Iowa - Recruiting 18 years to 60 years.
- Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis.
Domperidone

Nausea, Vomiting, or Genital Neoplasms, Female Clinical Trial using Fosaprepitant dimeglumine; Placebo

Odense University Hospital - Recruiting 18 years or older.
- A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin..
Fosaprepitant dimeglumine; Placebo

Pain, Nausea, Vomiting, or Anxiety Clinical Trial using Pediatric Integrative Medicine consult and service provision; Usual care

University of Alberta - Recruiting N/A to 16 years.
- Pilot Study of Pediatric Integrative Medicine in Pediatric Oncology.
Pediatric Integrative Medicine consult and service provision; Usual care

Nausea Clinical Trial using Acupressure bands; Version 1 handout; Version 1 MP3; Version 2 handout; Version 2 MP3

University of Rochester - Recruiting 18 years or older.
- Alternative Approaches for Nausea Control.
Acupressure bands; Version 1 handout; Version 1 MP3; Version 2 handout; Version 2 MP3

Postoperative Nausea and Vomiting Clinical Trial using Dexamethasone and Ondansetron; Placebo

Hopital Foch - Recruiting 18 years to 75 years.
- Should we Associate Dexamethasone and Ondansetron to Closed-loop Anesthesia to Reduce the Incidence of Postoperative Nausea and Vomiting After Bariatric Surgery?.
Dexamethasone and Ondansetron; Placebo

Nausea, Vomiting, or Chemotherapy Clinical Trial using Oral Aprepitant; Aprepitant

The Hospital for Sick Children - Recruiting 12 years to 18 years.
- Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents.
Oral Aprepitant; Aprepitant

Nausea, or Vomiting Clinical Trial using aprepitant; Ondansetron

University of Vermont - Recruiting 18 years or older.
- Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen.
aprepitant; Ondansetron

Gastroparesis Clinical Trial using Sancusor

Temple University - Recruiting 18 years to 65 years.
- Sancusor in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study..
Sancusor

PONV Clinical Trial using APD421; Placebo

Acacia Pharma Ltd - Recruiting 18 years or older.
- Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting.
APD421; Placebo

Nausea, or Vomiting Clinical Trial using Trimebutine Maleate (NEWBUTIN SR 300 mg Tab); Metoclopramide hydrochloride monohydrate

CM Chungmu Hospital - Recruiting N/A to 70 years.
- Trimebutine Maleate (NEWBUTIN SR 300 mg Tab) as a Prophylactic Anti-emetic Drug for Patients Who Underwent Arthroscopic Rotator Cuff Repair: a Randomized Controlled Study.
Trimebutine Maleate (NEWBUTIN SR 300 mg Tab); Metoclopramide hydrochloride monohydrate

Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Che Clinical Trial using Fosaprepitant; Dexamethasone; 5HT3 receptor antagonist; Ifosfamide-based chemotherapy (AI); Doxorubicin; Mesna; Ifosfamide; Vincristine

M.D. Anderson Cancer Center - Recruiting 18 years to 65 years.
- Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen.
Fosaprepitant; Dexamethasone; 5HT3 receptor antagonist; Ifosfamide-based chemotherapy (AI); Doxorubicin; Mesna; Ifosfamide; Vincristine

Nausea, Vomiting, or Metastatic Liver Cancer Clinical Trial using acupoint electric stimulation; tropisetron

Fudan University - Recruiting 18 years or older.
- Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE.
acupoint electric stimulation; tropisetron

Gastrointestinal Cancer, or Nausea Post Chemotherapy Clinical Trial using fosaprepitant dimeglumine

Barbara Ann Karmanos Cancer Institute - Recruiting 19 years or older.
- Prevention of Nausea and Vomiting Secondary to FOLFIRINOX Chemotherapy in Gastrointestinal Cancer Patients.
fosaprepitant dimeglumine

Pain Intractable, Delirium, Dyspnea, or Nausea Clinical Trial using Dexmedetomidine; Midazolam

Fraser Health - Recruiting 19 years or older.
- Dexmedetomidine Compared to Midazolam for Symptom Control in Advanced Cancer Patients: A Pilot Randomized Controlled Trial (RCT).
Dexmedetomidine; Midazolam

Pain, Nausea, or Anxiety Clinical Trial using CAM treatments

Bnai Zion Medical Center - Recruiting 18 years or older.
- Patient Reported Outcomes Following Complementary Medicine Treatments in Hospitalized Patients.
CAM treatments

Nausea, or Vomiting Clinical Trial using Fentanyl

Yonsei University - Recruiting 20 years to 60 years.
- .
Fentanyl